In 2022, American Urological Association updated the guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). A significant change has been made in treatment recommendations. The updated guideline no longer divided treatments into first-line through sixth-line tiers. Instead, treatment is categorized into behavioral/non-pharmacologic, oral medicines, bladder instillations, procedures, and major surgery. This change emphasizes the heterogeneity of IC/BPS patients and the importance of individualized treatment, overturns traditional unreasonable ideas about hierarchical and progressive treatment, and encourages patients and physicians to make treatment decisions together. At the same time, the panel emphasized the importance of early implementation of cystoscopy in patients suspected of Hunner lesions and warned against the possibility of pentosan polysulfate causing a unique retinal pigmentary maculopathy. Urinary reconstruction surgery was considered to only be used as a last resort for the treatment of IC/BPS, and there is uncertainty about the overall balance between benefits and risks/burdens. The updated guideline provides a new understanding and decision-making basis for the diagnosis and treatment of IC/BPS. However, it should be noted that the clinical characteristics of Chinese patients should be considered in practice and the application of the guideline should be localized.
2022年美国泌尿外科学会更新了间质性膀胱炎/膀胱疼痛综合征（IC/BPS）的诊断和治疗指南，本次更新在治疗推荐方面做了大幅改动，不再推荐一线至六线治疗，而将目前已有的治疗方案分为五大类，包括行为和非药物治疗、口服药物、膀胱药物灌注、经尿道手术和骶神经调节，以及尿路重建手术。这种改变强调了IC/BPS患者的异质性及个体化治疗的重要性，打破了长期以来层级递进式的治疗观念，并且鼓励患者参与治疗方案的决策。同时，专家委员会强调了IC/BPS病程早期进行膀胱镜检查的重要性，也指出应用戊聚糖多硫酸盐导致视网膜色素性黄斑病的风险，并且认为尿路重建手术仅作为治疗IC/BPS的最后手段，且收益风险比不明确。更新后的指南就IC/BPS的诊断和治疗为医师提供了新的认识和决策依据，但需要注意的是，实践中需考虑中国患者的临床特征，做到指南应用本土化。.
Zhonghua wai ke za zhi [Chinese journal of surgery]. 2024 Feb 01 [Epub]
L Zeng, J B Bi
Department of Urology, First Hospital of China Medical University, Shenyang 110001, China.